Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase

Pharming Group (NASDAQ:PHAR) saw strong trading volume on Thursday . 2,510 shares traded hands during trading, a decline of 2% from the previous session’s volume of 2,557 shares.The stock last traded at $9.37 and had previously closed at $10.45.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Stock Performance

The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $10.70 and its 200 day moving average is $11.35. The stock has a market capitalization of $671.10 million, a PE ratio of -71.42 and a beta of 0.20.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $71.83 million. Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. On average, equities research analysts predict that Pharming Group will post -0.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC purchased a new position in Pharming Group (NASDAQ:PHAR) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 17,710 shares of the company’s stock, valued at approximately $202,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.